Overview and Scope
A small-molecule active pharmaceutical ingredient (API) is any substance or mixture of organic substances or compounds with a low molecular weight intended to be used as the active ingredient in the manufacture of a drug or medicinal product. A small molecule active pharmaceutical ingredient (API) is used as raw materials in the manufacturing of pharmaceutical drugs.
Sizing and Forecast
The small molecule active pharmaceutical ingredient market size has grown strongly in recent years. It will grow from $181.54 billion in 2023 to $196.44 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to regulatory approvals, patent expirations, disease prevalence, pricing pressures, clinical trial outcomes.
The small molecule active pharmaceutical ingredient market size is expected to see strong growth in the next few years. It will grow to $265.6 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to precision medicine, specialty therapeutics, sustainability initiatives, telehealth adoption, integration of AI. Major trends in the forecast period include outsourcing trends, targeted therapies, digitalization in pharma, virtual clinical trials, advanced analytics.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/small-molecule-active-pharmaceutical-ingredient-global-market-report
Segmentation & Regional Insights
The small molecule active pharmaceuticals market covered in this report is segmented –
1) By Type: Synthetic, Chemical, Biological
2) By Therapeutic Type: Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, Dermatology, Urology
3) By Manufacturing Method: In-House, Contract
4) By Application: Clinical, Commercial
North America was the largest region in the small molecule active pharmaceutical ingredient market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the small molecule active pharmaceutical ingredient market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7948&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of diseases is a major driver propelling the small molecule active pharmaceutical ingredient (API) market. A disease is a particular abnormal condition, a disorder of a structure or function, that affects the body of the patient. Active pharmaceutical ingredients (APIs) are the active components in a pharmaceutical drug that produce the required effect on the body to treat various conditions. For instance, according to Cancer Research UK, a UK-based cancer research organization, approximately 18 million new cancer cases were detected in 2020. Further, there would be 28 million new cancer cases globally each year by 2040, a 54.9% increase over 2020, and is predicted to be more prominent in males (60.6% increase) than girls (48.8% increase). Further, in March 2023, according to the reports shared by the American Society of Clinical Oncology (ASCO), a US-based professional organization, it was estimated that more than 12,000 people in the US were diagnosed with neuroendocrine tumors yearly. Further, approximately 171,000 people were living with this diagnosis in 2023. Cardiovascular diseases have resulted in the deaths of 17.9 million people worldwide. Therefore, the increasing prevalence of diseases will continue to be the key driver in the small molecule API market.
Key Industry Players
Major companies operating in the small molecule active pharmaceutical ingredient market report are Pfizer Inc., BASF SE, Roche Holding AG, F. Hoffmann-La Roche Limited, AbbVie Inc., Allergan plc, Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Glaxo Smith Kline plc, China Resources Pharmaceutical Group Limited, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Viatris Inc., Teva Pharmaceutical Industries Limited, Johnson Matthey plc, Astellas Pharma Inc., Albemarle Corporation, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Dr Reddy’s Laboratories Limited, Siegfried Holding AG, Albany Molecular Research Inc., Cipla Inc., Cambrex Corporation, Daiichi Sankyo Company Ltd., Eisai Co Ltd., Otsuka Holdings Co Ltd.
The small molecule active pharmaceutical ingredient market report table of contents includes:
1. Executive Summary
2. Small Molecule Active Pharmaceutical Ingredient Market Characteristics
3. Small Molecule Active Pharmaceutical Ingredient Market Trends And Strategies
4. Small Molecule Active Pharmaceutical Ingredient Market – Macro Economic Scenario
5. Global Small Molecule Active Pharmaceutical Ingredient Market Size and Growth
.
.
.
32. Global Small Molecule Active Pharmaceutical Ingredient Market Competitive Benchmarking
33. Global Small Molecule Active Pharmaceutical Ingredient Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Small Molecule Active Pharmaceutical Ingredient Market
35. Small Molecule Active Pharmaceutical Ingredient Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
